



AUG 3 0 2002

TECHNOLOGY CENTER R3700

In re application of: Hesson, et al.

Serial No.: 09/908,985 Art Unit: 1761
Filing Date: July 19, 2001 Examiner: Unknown
For: Kits and Compositions Supporting Intracranial Perfusions.

Docket No. 358381-101

Commissioner for Patents

Commissioner for Patents Washington, DC 20231

I hereby certify that this correspondence is being deposited with sufficient postage with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on July 19, 2002.

By: Sprifer Cliver

Jennifer Cliver

## **INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.56**

Applicants herein make available to the Patent and Trademark Office copies of the documents:

- ☐ listed on enclosed Form PTO/SB/08A/B (Formerly PTO-1449), in accordance with 37 CFR 1.98(a)(2); and
- listed on enclosed copies of Forms PTO-1449, PTO-892 or PTO/SB/08A/B, which forms recited the application information for applications to which this application claims priority under 35 U.S.C. §120, but have been edited to indicate the current application data. Pursuant to 37 CFR 1.98(d), NO COPIES OF THESE DOCUMENTS ARE ENCLOSED. The prior applications that provide the source of these documents are:

Serial No. \_\_\_\_\_\_, filed \_\_\_\_\_;
Serial No. \_\_\_\_\_\_, filed \_\_\_\_\_;

The Examiner is requested to consider carefully the complete text of these references in connection with the examination of this application. It is believed that the Examiner will concur with Applicant's belief that the foregoing references do not adversely affect the patentability of the subject matter presently claimed, taken alone or in combination.

It is requested that the listed references be included in the "References Cited" portion of any patent issuing from this application.

Under 37 CFR 1.97(i), Applicants understand that non-complying Information Disclosure Statements will be placed in the file but not considered by the Office, however, under Reply to Comment 8 of the Federal Register, page 2024, Applicants will be informed when information is not considered.

(1)	This Information Disclosure Statement is being filed:		
	within three months of the filing date of the pat	ent application.	
	within three months of the date of entry into the forth in 37 CFR 1.491 of the international appli		
	before the mailing date of a first Office Action	on the merits.	
	after the mailing date of the first Office Action the mailing date of a Final Office Action under Notice of Allowance under 37 CFR 1.311, and accompanied by:	37 CFR 1.116 or a	
	the Statement under 37 CFR 1.97(e) (	see "Statement" below);	
or			
	the Fee of \$180.00 set forth in 37 CFF	R 1.17(p); or	
	No fee is owed by the applicants.		
	After the mailing date of a Final Office Action Notice of Allowance under 37 CFR 1.311, and accompanied by the Statement under 37 CFR 1 requesting consideration of the Information District the Petition Fee of \$130.00 set forth in 37 CFR "Statement," "Petition," and "Fees" below).	accordingly is .97(e), a Petition closure Statement and	
(2)	Statement		
	The undersigned attorney hereby states that excontained in the Information Disclosure Statem communication from a foreign patent office in a patent application not more than three months programmed information Disclosure Statement.	ent was cited in a a counterpart foreign	
	(If this box is checked, do not check any further Stateme	nt boxes.)	

	The person signing immediately below hereby states that no item of information contained in the Information Disclosure was cited in a communication from a foreign patent office in a counterpart foreign patent application or, to the knowledge of the person signing after making reasonable inquiry, was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.	
The per	son making the statement is:	
	the inventor(s) who sign(s) below:	
	Signature of the Inventor(s)	
	Typed or Printed Name of the Inventor(s)	
	or	
	a person who is substantively involved in the preparation or prosecution of the application, and who is associated with the inventor(s), or with the assignee, or with anyone to whom there is an obligation to assign the application (37 CFR 1.565(c)) and who signs below:	
	Signature of the Person(s)	
	Typed or Printed Name of the Person	
	Address of Person Signing	
	or	
	the undersigned attorney who signs on the basis of the information:	
	supplied by the inventor(s).	
1	supplied by an individual designated in 37 CFR 1.56(c).	
1	in the attorney's file.	
-	Signature of the Attorney	

(3)	Petition		
		Applicants hereby petitions the Assistant Commissioner to consider the references listed in this Information Disclosure Statement and on the enclosed Form PTO/SB/08A and 08B (Formerly PTO-1449), in the examination of the above-identified patent application. (This box checked only if a Final Office Action has issued)	
(4)	Fees		
	$\boxtimes$	No Fee is owed by the applicants.	
		The IDS Fee of \$180.00 under 37 CFR 1.17(p) is enclosed herewith.	
		The Petition Fee of \$130.00 under 37 CFR 1.17(i)(1) is enclosed herewith.	
(5)	) Method of Payment of Fees		
		Attached is a check in the amount of \$240.00.	
		Charge Account No. 04-0480 in the amount of \$180.00. (A duplicate of this request is attached).	
(6)	Authori	Authorization to Charge Additional Fees	
	$\boxtimes$	If any additional fees are owed in connection with this communication, please charge Deposit Account No. 04-0480.	
(7)	Instruct	ions as to Overpayment	
	$\boxtimes$	Please credit Account No. 04-0480 for any overpayment.	
		Please refund Dechert Price & Rhoads in the amount of \$	

A prompt and favorable response is earnestly solicited.

Respectfully submitted,

Arthur E. Jackson

Registration No. 34,354

DECHERT
Princeton Pike Corporate Center

PO Box 5218

Princeton, New Jersey 08543-5218

Fax: (609) 620-3259

Attn: Arthur E. Jackson, Esq.

(609 620-3254)

136255.1.07